• Orla M Fitzpatrick, Catherine Murphy, Erica Duignan, Keith Egan, Bryan T Hennessy, Liam Grogan, Adrian Murphy, Oscar S Breathnach, Jarushka Naidoo, and Patrick G Morris.
• Cancer Clinical Trials and Research Unit, Medical Oncology Department, Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland. orlafitzpatrick@rcsi.com.
• Ir J Med Sci. 2022 Dec 1; 191 (6): 248724912487-2491.

BackgroundClinical trials are often considered the gold standard in cancer care. However, patients face barriers in trial participation including distances to cancer centres and personal costs including changing employment status, cost of medications, inpatient admissions, and parking tariffs.AimOur aim was to compare the distances patients travelled for clinical trials compared to those receiving standard systemic anticancer therapy (SACT). We also investigated the additional costs associated with this.MethodsThis was a retrospective review of electronic patient medical records. The distance from the patients' home address to Beaumont was calculated as a one-way journey in kilometres. Patients attending for clinical trials were compared to those receiving standard of care SACT.ResultsA total of 271 patients receiving standard SACT over a 5-day period and 111 patients enrolled on 24 clinical trials were included. The median one-way distance travelled by patients enrolled in clinical trials was 41.4 km, compared to 14 km in those patients' receiving standard of care SACT. The median estimated cost was €13 vs €4.20 for those enrolled on clinical trials compared to those receiving standard of care treatment, respectively.ConclusionPatients enrolled on clinical trials often travel more than twice as far to receive their anti-cancer treatment compared to those receiving standard of care SACT and incur an increased cost of travel expenses.© 2022. The Author(s).

11 keywords...

hide…